4.6 Article

Nickel release from earrings purchased in the united states: the San Francisco earring study

Journal

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 58, Issue 6, Pages 1000-1005

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2008.03.017

Keywords

-

Categories

Ask authors/readers for more resources

Background: Nickel sensitization is frequent among US patients with dermatitis and in the general population. In Europe, decreasing prevalences of nickel sensitization are observed as a result of the European Union Nickel Directive. However, no directive exists in the United States. Objectives: We sought to examine nickel release from inexpensive earrings and discuss possible methods of reducing nickel exposure among consumers. Methods: A total of 34 different stores and artists were visited. A total of 277 earrings were purchased and examined with the dimethylglyoxitne (DMG) test. Results: DMG-positive earrings were identified from local artists (69%) and tourist stores (42.9%) but also chain stores targeting young (24.1%) and mature (1.7%) women. No correlation between price and outcome of DMG testing was identified. Limitations. Our study does not reflect buying trends in the United States. Pretreatment of earrings with artificial sweat was not performed and the DMG may lead to both false-positive and false-negative results. Conclusions: Nickel exposure from inexpensive earrings is frequent in the United States. A regulatory governmental intervention may be warranted.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Dermatology

COVID-19 vaccine side effects in patients with and without atopic dermatitis

Leah Shin, Shahin Shahsavari, Jennifer Laborada, Claudia Lee, Jacob Pontoppidan Thyssen, Jashin J. Wu

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Letter Dermatology

Disease burden of moderate-severe atopic dermatitis by use of systemic treatment: Results from the Danish Skin Cohort

I. Vittrup, A. G. Frostrup, S. T. Gren, S. F. Thomsen, J. J. Wu, P. Schmid-Grendelmeier, J. -T. Maul, A. Egeberg, J. P. Thyssen

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Letter Dermatology

Treatment of chronic hand eczema with dupilumab-A retrospective follow-up study

Caroline Meyer Olesen, Yasemin Topal Yueksel, Claus Zachariae, Tamara Theresia Lund, Tove Agner, Tonny Studsgaard Petersen, Jacob Pontoppidan Thyssen

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Dermatology

Association of homelessness and skin conditions: a Danish population-based cohort study

Sandra F. Nilsson, Zarqa Ali, Thomas M. Laursen, Jacob P. Thyssen, Alexander Egeberg, Merete Nordentoft, Carsten Hjorthoj, Simon F. Thomsen

Summary: This study examines the association between homelessness and diagnosed skin conditions, prescribed medication, and type of consultation. The findings suggest that homelessness is associated with an increased risk of skin conditions, but a lower occurrence of skin cancer diagnosis. Individuals experiencing homelessness have different diagnostic and medical patterns for skin disorders compared to those not experiencing homelessness.

BRITISH JOURNAL OF DERMATOLOGY (2023)

Article Dermatology

Circulating biomarkers are associated with disease severity of chronic hand eczema and atopic dermatitis

Anna S. Quaade, Xing Wang, Julie B. K. Solberg, Nina H. Ulrich, Benjamin D. McCauley, Jacob P. Thyssen, Christine Becker, Jeanne D. Johansen

Summary: This study characterized the plasma inflammatory signature of chronic hand eczema (CHE) and found that severe CHE without a history of atopic dermatitis (AD) is associated with systemic Th2-driven inflammation. Targeting type 2 inflammation could be effective in treating various subtypes of CHE.

BRITISH JOURNAL OF DERMATOLOGY (2023)

Article Dermatology

Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis

Thomas Bieber, Jacob P. Thyssen, Alan D. Irvine, Yuichiro Tsunemi, Yun-Fei Chen, Luna Sun, Andrea Schloebe, Elisabeth Riedl, Michael J. Cork

Summary: Early improvement in signs and symptoms during treatment with baricitinib can predict clinical response at week 16, offering guidance for dermatologists in selecting treatment strategies for patients with moderate-to-severe AD.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2023)

Article Dermatology

The Proteome of Hand Eczema Assessed by Tape Stripping

Julie B. K. Solberg, Anna S. Quaade, Lylia Drici, Karolina Sulek, Nina H. Ulrich, Marianne B. Lovendorf, Jacob P. Thyssen, Matthias Mann, Beatrice Dyring-Andersen, Jeanne D. Johansen

Summary: The noninvasive tape strip method in combination with liquid chromatography-mass spectrometry proteomics can be used to analyze skin protein expression in patients with hand eczema (HE), and has potential for subtype differentiation and biomarker discovery. HE lesional samples exhibit increased expression of immune-related markers and decreased expression of structural barrier proteins compared to healthy skin. The subtype differences in HE are restricted to the lesional areas and include increased expression of skin barrier-related proteins independently of concurrent atopic dermatitis.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)

Article Dermatology

Drug Survival of Adalimumab, Secukinumab, and Ustekinumab in Psoriasis as Determined by Either Dose Escalation or Drug Discontinuation during the First 3 Years of Treatment- a Nationwide Cohort Study

David Thein, Nana A. L. Roseno, Julia-Tatjana Maul, Jashin J. Wu, Lone Skov, Lars Erik Bryld, Mads K. Rasmussen, Kawa Khaled Ajgeiy, Simon Francis Thomsen, Jacob P. Thyssen, Alexander Egeberg

Summary: The real-world effectiveness of biologics in treating psoriasis was examined using a nationwide registry. The results showed that the risk of discontinuation or off-label dose escalation was lower for secukinumab compared to ustekinumab, but higher for adalimumab. However, the risk of discontinuation was higher for both secukinumab and adalimumab. For patients who were bio-naive, the risk of discontinuation was comparable between secukinumab and ustekinumab.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)

Article Dermatology

Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics

J. P. Thyssen, D. Thaci, T. Bieber, M. Gooderham, M. de Bruin-Weller, W. Soong, K. Kabashima, S. Barbarot, P. C. Luna, J. Xu, X. Hu, Y. Liu, E. M. Raymundo, B. M. Calimlim, C. Nduaka, A. Gamelli, E. L. Simpson

Summary: This study evaluated the efficacy of oral Janus kinase inhibitor upadacitinib in subgroups of patients with moderate-to-severe atopic dermatitis (AD). The results showed that upadacitinib consistently improved skin condition and itch in these subgroups, regardless of age, sex, race, disease severity, body surface area involvement, past treatment history, etc. These findings support upadacitinib as a suitable treatment option for a variety of AD patients.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Letter Dermatology

Association between atopic dermatitis/eczema and arthritis among US adults

Brandon Smith, Priya Engel, Michael R. R. Collier, Shivali Devjani, Jacob P. P. Thyssen, Jashin J. J. Wu

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Dermatology

A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis

Andreas Wollenberg, Jacob P. Thyssen, Thomas Bieber, Gary Chan, Urs Kerkmann

Summary: The PRAC of the EMA has reevaluated the benefit-risk balance of oral JAKi and recommended their use only if no suitable alternatives are available. They should be used with caution in patients with certain risk factors, and the European Commission has made a final decision in March 2023.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Endocrinology & Metabolism

A Skin Care Program to Prevent Skin Problems due to Diabetes Devices in Children and Adolescents: A Cluster-Controlled Intervention Study

Anna Korsgaard Berg, Annemarie Cecilie Grauslund, Fiona Sorensen, Steffen Ullitz Thorsen, Jacob P. Thyssen, Claus Zachariae, Jannet Svensson

Summary: Diabetes devices used for insulin delivery and blood glucose measurement often cause skin problems, such as eczema and wounds. This study aimed to provide evidence-based information on the efficacy of a basic skin care program in preventing these skin problems. The results showed that the program partially prevented diabetes device-induced skin reactions, but additional preventive strategies are needed for optimized prevention.

DIABETES CARE (2023)

Article Dermatology

A value-based healthcare model for initiating and switching psoriasis therapies-Results from the prospective multicentre IMPROVE study

V. W. Nielsen, C. B. Johansen, T. Todberg, L. Skov, C. V. Nissen, R. Dodge, A. Egeberg, J. P. Thyssen, S. F. Thomsen

Summary: This study evaluated a value-based healthcare model for psoriasis patients, remunerating treatment based on patient reported outcomes and successfully predicting expected outcomes to incentivize over-performance.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Letter Dermatology

The vIGA-AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema Council

Robert Bissonnette, Eric Simpson, Lawrence F. Eichenfield, Emma Guttman-Yassky, Jonathan I. Silverberg, Lisa A. Beck, Lorena Mija, Jacob P. Thyssen, Thomas Bieber, Kenji Kabashima, Elaine Siegfried, Georg Stingl, Peter van de Kerkhof, Gil Yosipovitch, Carle Paul, Amy S. Paller

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Allergy

Limited clinical role of blood eosinophil levels in early life atopic disease: A mother-child cohort study

Signe Kjeldgaard Jensen, Mathias Elsner Melgaard, Casper-Emil Tingskov Pedersen, Luo Yang, Nilo Vahman, Jacob P. Thyssen, Ann-Marie M. Schoos, Jakob Stokholm, Hans Bisgaard, Bo Chawes, Klaus Bonnelykke

Summary: Blood eosinophil count at 18 months was not associated with current wheezing/asthma or atopic dermatitis, while blood eosinophil count at age 6 years was associated with increased occurrence of current wheezing/asthma, atopic dermatitis, and allergic rhinitis. Blood eosinophil count at 18 months did not predict persistence or development of recurrent wheeze/asthma or atopic dermatitis at age 6 years.

PEDIATRIC ALLERGY AND IMMUNOLOGY (2023)

No Data Available